Liposome-encapsulated therapies: Precision medicine for inflammatory lung disorders

Abstract

Liposomes have emerged as the preferred choice over other nanocomposites for transporting a wide range of hydrophobic and hydrophilic compounds with therapeutic potential. This is primarily due to their exceptional degradation ability, compatibility within biological systems, and minimal immunogenicity. Liposomes have demonstrated their ability to enhance the solubility and distribution of medications. Moreover, they can undergo surface modifications to enable sustained, prolonged, and targeted release. Inflammatory lung disorders such as asthma, lung cancer, lung damage, tuberculosis, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease (COPD) greatly benefit from liposomes' unique treatment and management qualities. This article provides an overview of the current understanding of liposomal systems' efficacy in drug delivery for managing pulmonary inflammatory diseases. • Liposomes enable precise drug delivery for inflammatory lung disorders. • They improve solubility, bioavailability, and reduce systemic toxicity. • Liposomal therapies show promise in asthma, COPD, and pulmonary fibrosis. • Modified liposomes enhance targeting and therapeutic efficacy. • Further research is needed to optimize clinical applications.